From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances

WIB_icon

Equal Access to Treatment Erases Difference in Outcomes Between White and African American Patients...

If African American patients with multiple myeloma (MM) are given equal access to treatments, they have outcomes that are as good as or better...
WIB_icon

Evaluating Safety and Efficacy of Venetoclax Plus R-CHOP in Non-Hodgkin Lymphoma

According to results from the phase Ib CAVALLI study, treatment with the oral BCL2 inhibitor venetoclax, combined with standard immunochemotherapy, induced high response rates...
WIB_icon

Study Finds Urgent Need for Sickle Cell Disease Screening Among African Refugees in Italy

Most refugees who arrive at the Mediterranean coast of Italy and other southern European countries are leaving areas where sickle cell disease (SCD) is...
WIB_icon

Walking Speed Predicts Frailty, Survival, and Other Outcomes in Older Patients With Blood Cancers

Walking speed was a reliable indicator of frailty among older patients with blood cancers, and this frailty measure was a more accurate predictor of...

TKIs Linked to Increased Cardiovascular and Arteriothrombotic Events in Chronic-Phase CML

In patients with chronic-phase chronic myeloid leukemia (CML), treatment with tyrosine kinase inhibitors (TKIs) has been shown to increase the risk of cardiovascular and...
WIB_icon

Post-Transplant Pembrolizumab Consolidation Improves PFS in Relapsed/Refractory Hodgkin Lymphoma

In patients with high-risk, relapsed/refractory classical Hodgkin lymphoma (cHL) who have undergone autologous hematopoietic cell transplantation (AHCT), consolidation therapy with the PD-1 inhibitor pembrolizumab...
WIB_icon

New Study Supports “R2” Regimen in Previously Untreated Follicular Lymphoma

The combination of lenalidomide and rituximab, known as the R2 regimen, improved progression-free survival (PFS), time to next treatment (TTNT), and complete response (CR)...

Hematologic Malignancies Drive In-Hospital Death Rates

In the past 17 years, the overall rate of in-hospital deaths among patients with hematologic malignancies has decreased by 30 percent, with a corresponding...
WIB_icon

Higher Dose, Longer Duration of Eltrombopag Improves Likelihood of Response in Refractory Severe Aplastic...

The thrombopoietin receptor agonist eltrombopag was approved by the U.S. Food and Drug Administration for the treatment of adults with refractory severe aplastic anemia...
WIB_icon

Is “Watching and Waiting” Enough for Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma?

For patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), active surveillance appeared to be a feasible initial management strategy, according to an analysis published in...
Advertisement

Current Issue

July 2019 Bonus Mid-Year Edition, Volume 5, Issue 9

This issue features a look at research espionage, coverage from the ASCO and EHA annual meetings, and more.